Rodrigues Célia Fortuna, Silva Francisco
Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU (IUCS-CESPU), 4585-116 Gandra PRD, Portugal.
UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra PRD, Portugal.
Pathogens. 2025 May 24;14(6):525. doi: 10.3390/pathogens14060525.
Antibiotics have revolutionized medicine, with (fluoro)quinolones emerging as one of the most impactful classes of antibacterial agents. Since their introduction, four generations of (fluoro)quinolones have been developed, demonstrating a broad spectrum of activity, favourable pharmacokinetics, and clinical efficacy. However, the rise of multidrug-resistant pathogens has posed significant challenges to their continued effectiveness, particularly in healthcare settings. Among the main resistant species, , particularly methicillin-resistant strains (MRSA), , spp. ( and ), spp., and are the most important. This critical literature review provides an updated perspective on (fluoro)quinolones (old and new), encompassing their spectrum of activity, pharmacokinetics, mechanisms of resistance, and the role of antimicrobial stewardship in preserving their utility, to address the growing threat of resistance.
抗生素彻底改变了医学，（氟）喹诺酮类药物成为最具影响力的抗菌药物类别之一。自问世以来，已开发出四代（氟）喹诺酮类药物，显示出广泛的活性谱、良好的药代动力学和临床疗效。然而，多重耐药病原体的出现对其持续有效性构成了重大挑战，尤其是在医疗环境中。在主要的耐药菌种中， ，特别是耐甲氧西林菌株（MRSA）， ， 属（ 和 ）， 属，以及 是最重要的。这篇重要的文献综述提供了关于（氟）喹诺酮类药物（新旧）的最新观点，包括它们的活性谱、药代动力学、耐药机制以及抗菌药物管理在保持其效用方面的作用，以应对日益增长的耐药威胁。
